AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8003844
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate (APD) 30 mg as a single infusion every 3 months
Trial: 8003844
Drug: Oral fluoride
RxNorm normalized name: sodium fluoride Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluoride (20‐30 mg F/day)
Trial: 2571403
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) aqueous nasal spray
Trial: 28880972
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MVA-5T4 and cyclophosphamide
Trial: 17094524
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg cisatracurium [2ED95]
Trial: 17094524
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg rocuronium [2ED95]
Trial: 17094524
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.075 mg/kg cisatracurium [1ED95] plus 0.3 mg rocuronium [1ED95]
Trial: 9921571
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of 1.6 ml (480 mcg) of G-CSF
Trial: 9921571
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of 0.8 ml each of G-CSF
Trial: 3310318
Drug: Metformin (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1.7 g/day)
Trial: 574098
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Metformin + Clofibrate)
Trial: 31735410
Drug: Acute-phase cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute-phase cognitive therapy (A-CT)
Trial: 31735410
Drug: Continuation-phase treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation-phase treatment (CCT)
Trial: 31735410
Drug: Matched pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched pill placebo
Trial: 31153781
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (HC) 100mg every eight hours until the second postoperative day
Trial: 23363495
Drug: Fractional dose
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional dose of IPV (one fifth of a full dose) administered intradermally
Trial: 23363495
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of IPV administered intramuscularly
Trial: 9447478
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/day for 3 days)
Trial: 11476796
Drug: Subcutaneous hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous hCG (5,000 IU)
Trial: 11476796
Drug: Intramuscular hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hCG (5,000 IU)
Trial: 11476796
Drug: Both subcutaneous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both subcutaneous and intramuscular hCG
Trial: 9570254
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (750 mg b.d.)
Trial: 9570254
Drug: Intravenous cephazolin
RxNorm normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cephazolin (1 g b.d.)
Trial: 27836205
Drug: Standard skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard skin preparation without CMS
Trial: 22956434
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus (TAC) plus prednisone for 12 months
Trial: 22956434
Drug: Prednisone combined
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone combined with intravenous cyclophosphamide (CYC) for 24 weeks
Trial: 22956434
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus (TAC) plus prednisone
Trial: 19700774
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral enoximone
Trial: 17145722
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily (Amlodipine-based regimen)
Trial: 17145722
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily (Atenolol-based regimen)
Trial: 15307550
Drug: Heparin coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin coated circuit and oxygenator (group H)
Trial: 9060560
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) filgrastim; 5 microg/kg/d
Trial: 3776949
Drug: 20% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% ethanol (6 ml)
Trial: 3776949
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (20 mg/kg iv)
Trial: 24642785
Drug: High-calcium (CAL)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calcium (CAL) supplementation (1400 mg of calcium)
Trial: 24642785
Drug: Control (CON)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CON) supplementation (400 mg of calcium)
Trial: 20516658
Drug: Low-dose beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose beta-carotene (30 mg/day)
Trial: 20516658
Drug: High-dose beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose beta-carotene (90 mg/day)
Trial: 18541125
Drug: Maxacalcitol lotion
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maxacalcitol lotion
Trial: 15825531
Drug: TPD ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPD ophthalmic solution (0.5% tropicamide, 0.5% phenylephrine, 0.1% diclofenac)
Trial: 15825531
Drug: Individual solutions
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual solutions (0.5% tropicamide/0.5% phenylephrine, 5% phenylephrine, 0.1% diclofenac)
Trial: 15825531
Drug: TPD ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPD ophthalmic solution
Trial: 9463561
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (10 mg per day)
Trial: 7944840
Drug: Inappropriate medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate medication use
Trial: 7944840
Drug: Subjects using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects using three or more prescription drugs
Trial: 3295625
Drug: Low-dose human
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) at 1.2 X 10(6) IU/m2 for 28 days, subcutaneously (s.c.)
Trial: 3295625
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose treatment of Hr IFn-2c at 1.2 X 10(5) IU/m2, s.c. daily increasing to a well-tolerated dose
Trial: 31777234
Drug: Cilostazol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (50 mg/time, 2 times/d) and Epalrestat (50 mg/time, 3 times/d)
Trial: 29121625
Drug: Face-to-face delivery
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face delivery of the Green Prescription
Trial: 22152723
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg subcutaneously at 8-week intervals
Trial: 16502769
Drug: Ramipril test
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril test formulation from Laboratórios Biosintética Ltda (5 mg)
Trial: 16502769
Drug: Triatec formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triatec formulation from Aventis Pharma (5 mg)
Trial: 15208585
Drug: Albuterol metered‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol metered‐dose inhalers (16 cumulative puffs, doubled at 15-minute intervals)
Trial: 11085051
Drug: HRT +
RxNorm normalized name: Hormone Replacement Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT + K (TTS natural estrogens 50 micrograms/day with progestin and Kava‐Kava extract at a dose of 100 mg, n=13)
Trial: 11085051
Drug: ERT +
RxNorm normalized name: Enzyme Replacement Therapy Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERT + K (TTS natural estrogens 50 micrograms/day and Kava‐Kava extract at a dose of 100 mg, n=11)
Trial: 7689778
Drug: Reduced doses
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced doses of alkylating agents
Trial: 31649304
Drug: Psilocybin (315
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (315 μg/kg PO)
Trial: 28541926
Drug: Statin +
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Statin + omega-3 PUFA 2.52 g/day
Trial: 28541926
Drug: Statin +
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Statin + omega-3 PUFA 2.52 g/day + CoQ10 200 mg/day
Trial: 28541926
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (unaltered statin therapy)
Trial: 24348043
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E tocotrienol-rich fraction (TRF) 180 mg tocotrienols, 40 mg tocopherols
Trial: 24348043
Drug: Placebo (0.48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.48 mg tocotrienols, 0.88 mg tocopherols)
Trial: 21513530
Drug: School-based lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based lifestyle intervention programme including weekly lifestyle-lessons for children, teacher training, and parent training.
Trial: 16942618
Drug: Candesartan/HCTZ (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan/HCTZ (16 mg/12.5 mg) with passive compliance monitoring (Group B)
Trial: 16942618
Drug: Candesartan/HCTZ (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan/HCTZ (16 mg/12.5 mg) with DRC intervention program (Group C)
Trial: 16942618
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Group A)
Trial: 10861338
Drug: L-Carnitine (L-C)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Carnitine (L-C) 2 g twice daily for 8 weeks
Trial: 10861338
Drug: Placebo (lactose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose) 2 g twice daily for 8 weeks
Trial: 9182742
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing + 2% minocycline gel (S&Mi)
Trial: 9182742
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing + 25% metronidazole gel (S&Me)
Trial: 2422004
Drug: Org 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 2766 (synthetic ACTH4-9 analog), 40 mg daily for 6 months
Trial: 30212849
Drug: Abstinence-optimized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence-optimized treatment (A-OT): 3 weeks of prequit mini-lozenges, 26 weeks of nicotine patch + mini-lozenges, three in-person and eight phone counseling sessions, and 7-11 automated calls to prompt medication use
Trial: 30212849
Drug: Recommended usual
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended usual care (R-UC): 10 min of in-person counseling, 8 weeks of nicotine patch, and referral to quitline services
Trial: 27958384
Drug: EUS-guided ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EUS-guided ethanol injection (n=10)
Trial: 23856100
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day of oral olanzapine
Trial: 22800696
Drug: Yunnan Baiyao
RxNorm normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunnan Baiyao capsules (2 g/d) for 28 days after operation
Trial: 22800696
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (2 g/d) for 28 days after operation
Trial: 11719594
Drug: HLA-G*0104 or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-G*0104 or HLA-G*0105N allele presence
Trial: 18692637
Drug: Esmolol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (all doses)
Trial: 3300711
Drug: Postoperative CMF
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative CMF chemotherapy
Trial: 3300711
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (Control)
Trial: 10079452
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (bupivacaine 0.75%)
Trial: 7573090
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg hs (average dose 29.5 mg)
Trial: 2076392
Drug: Nifedipine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (80 mg per day)
Trial: 30601990
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear (CH) treatment in early group (EG)
Trial: 30601990
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear (CH) treatment in late group (LG)
Trial: 21063868
Drug: Red Bull®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Bull® Energy Drink (250 ml)
Trial: 9645979
Drug: 619C89 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 619C89 (up to 2.5 mg/kg loading plus 1.25 mg/kg/8 h maintenance)
Trial: 9645979
Drug: 619C89 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 619C89 (doses below 2 mg/kg + 1 mg/kg/8 h)
Trial: 9645979
Drug: 619C89 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 619C89 (2 mg/kg/8 h or more)
Trial: 7907174
Drug: Zidovudine and
RxNorm normalized name: zidovudine and lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine and didanosine combination therapy
Trial: 362874
Drug: phenylpropanolamine/aromatic oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenylpropanolamine/aromatic oil syrup
Trial: 362874
Drug: phenylpropanolamine syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenylpropanolamine syrup
Trial: 362874
Drug: aromatic oil
RxNorm normalized name: AROMATIC OILS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aromatic oil syrup
Trial: 362874
Drug: placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo syrup
Trial: 26267983
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg taken orally 30 minutes before endometrial biopsy
Trial: 20530522
Drug: Prasterone (DHEA)
RxNorm normalized name: prasterone (DHEA)
DrugBank: Prasterone sulfate (DB05804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prasterone (DHEA) 200 mg/day
Trial: 16181530
Drug: Yufeining pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yufeining pills taken orally for half a year
Trial: 12708207
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 microgram.Kg‐1) and Midazolam (0.02 mg.Kg‐1)
Trial: 8696067
Drug: Non-insulin dependent
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin dependent diabetes mellitus prevalence
Trial: 1997425
Drug: Oral immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunization with Salmonella typhi Ty21a
Trial: 1997425
Drug: Parenteral administration
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral administration of heat‐killed typhoid vaccine
Trial: 22072430
Drug: Ulimorelin 480
RxNorm normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulimorelin 480 μg/kg
Trial: 18160764
Drug: Catechin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catechin (500 mg: equivalent to 6 or 7 cups of green tea)
Trial: 16968503
Drug: Clarithromycin, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, amoxicillin, esomeprazole (Group A)
Trial: 1348405
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg cetirizine
Trial: 23390092
Drug: Peripheral blood
RxNorm normalized name: Peripheral blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood progenitor cell therapy
Trial: 21393394
Drug: Heparin (unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (unfractionated or low molecular weight [enoxaparin])
Trial: 21393394
Drug: Heparin-treated patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-treated patients (ELISA positive but platelet-activating antibody negative)
Trial: 21393394
Drug: Heparin-treated antibody-negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-treated antibody-negative control subjects
Trial: 19716489
Drug: Morphine-based postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-based postoperative PCA with preoperative anxiolytics prescribed
Trial: 19716489
Drug: Morphine-based postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-based postoperative PCA without preoperative anxiolytics prescribed
Trial: 19716489
Drug: Morphine-based postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-based postoperative PCA
Trial: 11478826
Drug: Enteral formula
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral formula supplemented with 22 g/l partially hydrolyzed guar (soluble fiber)
Trial: 8555550
Drug: Constant ultrafiltration
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant ultrafiltration with constant dialysate Na of 140 mEq/L (Group A)
Trial: 8555550
Drug: Sequentially decreasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequentially decreasing ultrafiltration with sequentially decreasing dialysate Na from 150 to 140 mEq/L (Group C)
Trial: 3310843
Drug: Baked rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baked rice (90 g, raw, cooked for 10 min at 160 degrees C after boiling)
Trial: 3310843
Drug: Boiled rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled rice (90 g, raw, boiled in salted water)
Trial: 28428736
Drug: Fructose supplementation
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose supplementation (4 g/kg BM)
Trial: 28428736
Drug: Glucose supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose supplementation (4 g/kg BM)
Trial: 25913040
Drug: MMF +
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF + Pantoprazole (PAN) 40 mg
Trial: 25913040
Drug: EC-MPS +
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EC-MPS + Pantoprazole (PAN) 40 mg
Trial: 19492646
Drug: platform-enlarged implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: platform-enlarged implants
Trial: 19492646
Drug: control implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control implants with an abutment as large as the implant platform
Trial: 19492646
Drug: control implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control implants with a reduced abutment
Trial: 19492646
Drug: submerged implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: submerged implants with an enlarged platform